PAREXEL International Experts to Address Solutions and Strategies for Commercial Success at ISPOR 17th Annual International Meeting

BOSTON, June 1, 2012 /PRNewswire/ -- Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address topics including observational data methods, commercialization, and coverage policy during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting, to be held June 2-6, 2012 in Washington, D.C. Attendees will have the opportunity to learn more about PAREXEL’s expertise and capabilities to support the global approval and access needed for commercial success. PAREXEL will be exhibiting at Stand 59 and 60.

The ISPOR meeting program features numerous sessions, which will be presented by PAREXEL experts, including:

Saturday, June 2|
Short Course: Patient Registries, 1:00 5:00 p.m.

• Track: Observational Data Methods
• Faculty: Leanne Larson, MHA, Vice President, Evidence Development, PAREXEL International

Sunday, June 3
Education Symposium: Defending Against the Double Dip: Practical Solutions and Strategies for Developing Products for Commercial Success through Improved Access by Utilizing Health Outcomes Data, 5:15 6:15 p.m.

• Moderator: Bob Paglia, RPh, Vice President, Commercialization, PAREXEL Consulting
• Speakers: Neal Mantick, BSPharm, MS, Senior Director & Global Head Observational Research, PAREXEL International; Charles A. Stevens, JD, MBA, Vice President & General Manager, PAREXEL Consulting; Marc Samuels, JD, President, HillCo Health

Monday, June 4
Poster Presentation Sessions

• PHP108: Analyzing the New Era of National Coverage Determinations (NCD’s) by The Centers for Medicare and Medicaid Services (CMS) Post Its Sipuleucel-T Decision, 8:30 a.m. 2:00 p.m.
• Speakers: Charles A. Stevens, JD, MBA, Vice President & General Manager, PAREXEL Consulting and Kimberly Miller, Director
• PMH53: Measuring Real World Outcomes by Incorporating Pro Data Collection into Patient Access Support Programs, 4:30 8:30 p.m.
• Speaker: Charles A. Stevens, JD, MBA, Vice President & General Manager, PAREXEL Consulting

Wednesday, June 6
Poster Presentations Session

• PCN135: Creating Oncology Coverage Policy: The Reliance on Compendia and Treatment Guidelines by 25 Private Payers in the United States, 8:30 a.m. 2:45 p.m.
• Speakers: Charles A. Stevens, JD, MBA, Vice President & General Manager, PAREXEL Consulting and Kimberly Miller, Director, PAREXEL Consulting

For more information about PAREXEL visit www.PAREXEL.com or Stands 59 and 60 during the meeting. Information about ISPOR can be found at http://www.ispor.org/Events/Main.aspx?eventId=38.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

SOURCE PAREXEL International Corporation